Crizotinib is superior to standard first-line pemetrexed plus platinum chemotherapy in patients with previously untreated, advanced ALK rearrangement-positive NSCLC, which is associated with a greater reduction in lung cancer symptoms and a significant improvement in quality of life [8]. Here, ALK is linked to lung cancer.